Bliss GVS Pharma: New Promoters & Directors Appointed, MD Resigns Post Acquisition
Anupam Rasayan India Ltd. and Mates Visa Consultancy Pvt. Ltd. acquired 47.95% stake in Bliss GVS Pharma on September 28, 2026, becoming new promoters. The company appointed three new directors: Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat. Managing Director Narsimha Shibroor Kamath resigned.
A change in promoters and the board of directors, especially after a significant share acquisition, typically has a high impact on the company's strategic direction, operations, and future prospects.
The change in control and appointment of new directors signifies a new strategic direction and potential for growth under new management, which is generally viewed positively by the market.
Bliss GVS Pharma Limited announced significant changes following the completion of a share purchase agreement (SPA) and open offer. On September 28, 2026, Anupam Rasayan India Limited, along with Mates Visa Consultancy Private Limited (PAC), acquired control of Bliss GVS Pharma by purchasing 5,09,84,595 equity shares, representing 47.95% of the company's equity share capital. This acquisition makes them the new promoters of the company.
In line with the change in control, the Board of Directors has appointed three new Non-Executive Non-Independent Directors: Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah, and Mr. Pramod Badrinarayan Kasat, all effective from September 28, 2026. Concurrently, Mr. Narsimha Shibroor Kamath has resigned from his position as the Managing Director of the company, effective the same date. The Board has also approved a draft Postal Ballot Notice to seek shareholder approval for the appointment of the three new directors.
The Board meeting, which commenced at 6:41 p.m. and concluded at 6:57 p.m. on September 28, 2026, noted these changes as part of the consummation of the transaction contemplated in the SPA dated May 23, 2026, and the Deed of Adherence dated July 17, 2026.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.